Table 5.
HRV values obtained during the follow-up study
| |
LF (ms
2
) |
LF% |
SDANN (ms) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient ID | BL | 1 M | 3 M | BL | 1 M | 3 M | BL | 1 M | 3 M |
|
223 |
1033.6 |
271 |
245.4 |
55.6 |
52.9 |
38.4 |
47.3 |
29 |
57 |
|
2400 |
2938 |
1101.5 |
284.3 |
68.4 |
47.1 |
36.3 |
48.5 |
70.3 |
68.7 |
|
1318 |
955.3 |
622.9 |
730.5 |
51.3 |
43.9 |
47.9 |
27.5 |
29.8 |
31.6 |
|
6794 |
6.7 |
227.4 |
49.5 |
1.9 |
39 |
20.1 |
34.8 |
31.1 |
101.8 |
|
1400 |
151.6 |
144 |
82.3 |
28.2 |
39 |
23.8 |
32.7 |
91.4 |
157.9 |
| 955.3(115.4,1509.7) | 271.0(206.6,742.5) | 245.4(74.1,395.9) | 51.3(21.6,58.8) | 43.9(39.0,48.5) | 36.3(22.9,40.8) | 34.8(31.4,47.6) | 31.1(29.6,75.6) | 68.7(50.6,115.8)* | |
SDANN, LF component and LF% indexes measured during the HD session are shown for each patient at the start (baseline, BL), after 1 month (1 M), when the hydration target was planned to be reached, and after 3 months (3 M). The last row shows the values of median (25°, 75° percentiles).
*Paired Wilcoxon signed test p-value = 0.06 (3 M vs. BL).